Cellular basis of uraemic cardiomyopathy: a role for erythropoietin?

Insulin resistance and altered glucose transporter 4 expression in experimental uremia

(2009) Dunja Aksentijević et al.   KIDNEY INTERNATIONAL

Ser9 phosphorylation of mitochondrial GSK-3β is a primary mechanism of cardiomyocyte protection by erythropoietin against oxidant-induced apoptosis

(2008) Katsuhiko Ohori et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury

(2008) Jarkko Piuhola et al.   CLINICAL SCIENCE

Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit

(2008) Erik Lipšic et al.   EUROPEAN JOURNAL OF HEART FAILURE

Transcription factor GATA-4 is involved in erythropoietin-induced cardioprotection against myocardial ischemia/reperfusion injury

(2008) Xiaohong Shan et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation

(2008) Ashwin Akki et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure

(2007) P Kalk et al.   BRITISH JOURNAL OF PHARMACOLOGY

Diazoxide acts more as a PKC-ɛ activator, and indirectly activates the mitochondrial KATP channel conferring cardioprotection against hypoxic injury

(2006) M-Y Kim et al.   BRITISH JOURNAL OF PHARMACOLOGY